Good morning, you're listening to Markets Desk.
AI infrastructure names caught a strong bid Tuesday as deal announcements from Qualcomm and Corning lifted the broader sector. Shares of Intel, Advanced Micro Devices, and related plays all moved higher, with investors treating the news as fresh confirmation that capital spending on AI buildout remains firmly intact.
Shifting to biotech, Goldman Sachs added Vertex Pharmaceuticals to its Conviction List, putting the firm's full weight behind the name. The bull case centers on a rock-solid core business in cystic fibrosis paired with a deliberate expansion into adjacent therapeutic areas, a combination Goldman sees as durable and underappreciated at current levels.
On the insider activity front, a director at Dycom Industries made a notable open-market purchase, acquiring seven hundred shares for roughly two hundred one thousand dollars. Insider buys of that size tend to draw attention because they represent discretionary capital from someone with direct visibility into the business, and Dycom operates squarely in the fiber and telecom infrastructure buildout space.
That's the tape. Markets Desk, signing off the floor.
